- U.S. FDA trial completed with excellent top-line data
- Leading position in genetic antimicrobial resistance biomarker testing strengthened by GEAR acquisition
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2016 and provided an outlook to coming months.
Recent Operational and Business Highlights
Unyvero US FDA Trial » Read more...
- New study from Great Britain verifies the advantages of antibiotic-loaded bone cement from Heraeus with femoral head fractures
- Older patients with concomitant diseases profit from locally applied antibiotics
Good news for World Antibiotics Day on November 18th. As local substances carriers, antibiotic-loaded bone cements from Heraeus help in the battle against implant-associated infections in orthopaedics and trauma surgery to prevent infection. This is demonstrated by a new randomised study* from Great Britain in which the use of double-loaded antibiotic bone cement following femoral head fracture led to a significant 66% reduction in infection risk with primary hip arthroplasties, as compared with bone cement with only one antibiotic. The COPAL® G+C antibiotic-loaded bone cement developed by Heraeus Medical contains antibiotics whose spectrum of activity combats the germs typically responsible for infections in the implant. » Read more...